Generic entry rifaximin?

See the DrugPatentWatch profile for rifaximin

How long until a generic version of rifaximin appears?
Rifaximin’s main patent covering its formulation and use for irritable bowel syndrome and hepatic encephalopathy expires in 2028. That is the earliest point at which a U.S. generic could be approved, assuming no secondary exclusivities or regulatory delays.

Which patents keep rifaximin off the generic market?
The key patent is U.S. Patent 7,770,947, which claims the oral, delayed‑release formulation that gives rifaximin its low systemic absorption. Other patents protect specific dosage strengths and the drug’s labeling for chronic use. These patents collectively provide an 8‑year exclusivity period, the longest for a small‑molecule antibiotic.

Which companies are chasing a generic and what are they doing?
In 2023, Novartis announced a partnership with a generic‑focused firm to file a new‑drug application in 2024. The company plans to submit an abbreviated application once the primary patents expire, targeting a 2026 filing to expedite approval.

Will a generic significantly lower the price?
Once approved, the price of rifaximin could fall by 70–80 %, similar to what happened with other antibiotics after generic entry. Health insurers may negotiate rebates, further reducing costs for patients.

Are there alternative drugs that could replace rifaximin?
Non‑antibiotic options such as eluxadoline for IBS‑diarrhea and loperamide for travelers’ diarrhea exist, but none match rifaximin’s unique gut‑specific profile. A generic would likely become the first affordable choice for hepatic encephalopathy treatment.

Is a biosimilar possible for rifaximin?
Because rifaximin is a small‑molecule drug, a biosimilar does not apply. The focus remains on generic chemically identical versions.

What regulatory hurdles still remain?
The FDA requires a demonstration of bioequivalence to the reference product and confirmation that the delayed‑release mechanism is maintained. Manufacturers must also provide data that their formulation does not increase systemic absorption, a key safety concern.

---

Sources
1. https://drugpatentwatch.com/patents/7,770,947
2. https://drugpatentwatch.com/patents/7,770,947#patent_details